The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
<b>Background</b>: Treprostinil, which is administered via continuous subcutaneous or intravenous infusion, is a medication applied in the treatment of pulmonary arterial hypertension (PAH). The dose of treprostinil is adjusted on an individual basis for each patient. A number of factors...
Saved in:
Main Authors: | Piotr Kędzierski, Marta Banaszkiewicz, Michał Florczyk, Michał Piłka, Rafał Mańczak, Maria Wieteska-Miłek, Piotr Szwed, Krzysztof Kasperowicz, Katarzyna Wrona, Szymon Darocha, Adam Torbicki, Marcin Kurzyna |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-01-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/13/1/172 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Peak steps to measure ‘‘capacity for activity’’: Actigraphy in the ADAPT registry with oral treprostinil
by: Daniel Lachant, DO, et al.
Published: (2025-05-01) -
Soluble ST2 protein as a new biomarker in patientswith precapillary pulmonary hypertension
by: Marta Banaszkiewicz, et al.
Published: (2020-09-01) -
Escalation as a way to resolve conflicts and contradictions
by: J. G. Evdokimova, et al.
Published: (2021-08-01) -
Individual Differences in Placebo Analgesia: Functional Connectivity and Neural Mechanisms [Letter]
by: Cao H, et al.
Published: (2025-02-01) -
Anticoagulation strategies for pediatric continuous renal replacement therapy
by: Aakash Chandran Chidambaram, et al.
Published: (2024-09-01)